Abingworth’s Adaptimmune Therapeutics ADAP Stock Holding History

Abingworth’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-250,000	Closed	-$1.44M	–	15
2018 Q4	$1.44M	Hold	250,000	–	–	1.31%	13
2018 Q3	$3.39M	Hold	250,000	–	–	2.02%	8
2018 Q2	$2.96M	Hold	250,000	–	–	1.69%	10
2018 Q1	$2.81M	Hold	250,000	–	–	1.74%	11
2017 Q4	$1.67M	Hold	250,000	–	–	1.21%	14
2017 Q3	$2.04M	Hold	250,000	–	–	1.42%	12
2017 Q2	$1.13M	Hold	250,000	–	–	0.9%	15
2017 Q1	$1.38M	Hold	250,000	–	–	1.02%	14
2016 Q4	$1M	Hold	250,000	–	–	0.84%	15
2016 Q3	$1.76M	Hold	250,000	–	–	1.69%	14
2016 Q2	$2.03M	Hold	250,000	–	–	2.13%	13
2016 Q1	$2.03M	Hold	250,000	–	–	1.88%	13
2015 Q4	$3.01M	Buy	+250,000	New	+$2.45M	1.82%	11

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth's ADAP Position: Q1 2019 in Review

Abingworth sold out of Adaptimmune Therapeutics (ADAP) in Q1 2019, closing a stake of 250,000 shares — an estimated $1.44M sold.

Abingworth first reported a position in ADAP in Q4 2015 and held it in 13 quarters. The position peaked at $3.39M in Q3 2018. 68 funds tracked by Wall St. Rank hold ADAP as of Q1 2019.

Abingworth reported no remaining Adaptimmune Therapeutics position as of Q1 2019 after selling out during the quarter.
Abingworth sold 250,000 Adaptimmune Therapeutics shares in Q1 2019, an estimated $1.44M.
Abingworth first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 13 quarters.
Abingworth's Adaptimmune Therapeutics position peaked at $3.39M in Q3 2018.
68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2019.

Based on Abingworth's 13F filing for Q1 2019, filed 15 May 2019.